HOME >> BIOLOGY >> NEWS
Other Highlights in the July 3 Issue of JNCI

Compound Delays Progression of Premalignant Lung Lesions:
A phase IIb study of anethole dithiolethione (ADT) in smokers with bronchial dysplasia (pre-malignant lesions in the lung) suggests that the compound is an effective chemopreventive strategy for lung cancer control. These findings appear in the July 3 issue of the Journal of the National Cancer Institute.

ADT is one of two organosulfur compounds that are being studied for their ability to stimulate the production of enzymes that detoxify carcinogens. ADT has been approved in Canada and Europe for the treatment of drug- and radiation-induced dryness of the mouth and other conditions. To examine the effectiveness of ADT as a chemopreventive agent in lung cancer, Stephen Lam, M.D., of the British Columbia Cancer Agency and the University of British Columbia, and his colleagues randomly assigned 112 current and former smokers with bronchial dysplasia to receive either ADT or a placebo for 6 months.

Compared with patients who received placebo, those who received ADT had a lower rate of progression by two or more grades of preexisting dysplastic lesions and a reduction in the appearance of new lesions. Side effects of ADT were minor and included gastrointestinal symptoms that subsided after dose reduction or completion of ADT treatment.

Vitamin B12 May be Effective Carrier of Anticancer Drug:
Vitamin B12, an essential micronutrient, is required by tumors in increased concentrations compared with normal tissue. Joseph A. Bauer, Ph.D., and Daniel J. Lindler, M.D., Ph.D., of the Cleveland Clinic Foundation, and their colleagues examined whether a vitamin B12 analogue could be used as a carrier molecule to direct a chemotherapy drug to tumor cells.

The authors attached nitric oxide, which is toxic when internalized by cells, to vitamin B12. When mice bearing human tumors were treated with this compound, the tumors regressed. However, when the mice
'"/>

Contact: Linda Wang
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
2-Jul-2002


Page: 1 2 3

Related biology news :

1. Other highlights in the September 1 JNCI
2. Other highlights in the August 18 JNCI
3. Other highlights in the August 4 JNCI
4. Other highlights in the July 7 JNCI
5. Other highlights in the June 16 JNCI
6. Other Highlights in the June 2 JNCI
7. Other highlights in the May 19 JNCI
8. Other highlights in the May 5 JNCI
9. Other highlights of the March 17 issue of JNCI
10. Other highlights in the March 3 issue of JNCI
11. Other highlights in the February 18 issue of JNCI

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Other Highlights the July Issue JNCI

(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ) ... Sensors Market Forecast and Opportunities 2020" report ... is projected to grow at a CAGR over ... industrial and healthcare sectors are the key application ... adoption of MEMS technology in sensors is growing ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Latin America . Annual estimates ...
(Date:3/17/2015)... MINNETONKA, Minn. , March 17, 2015 /PRNewswire/ ... sciences technology company specializing in clinical study management ... will be in attendance at ARENA,s Outsourcing in ... Cary, NC.  This event provides an excellent forum ... company,s easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
(Date:4/1/2015)... 1, 2015 Emerson Ecologics is excited to ... of Better Medicine . The conference will provide integrative ... a thriving and fulfilling practice. Scheduled ... Resort and Spa, the conference will be a one-of-a-kind, ... accomplish key projects and leave with an action plan ...
(Date:4/1/2015)... TORONTO , April 1, 2015 /PRNewswire/ - ... Securities Exchange: PBT.U), is pleased to announce that ... holds 54% equity, has entered into an agreement ... Biohaven,s first clinical trial with their lead compound ... the identification and development of clinical stage neuroscience ...
(Date:4/1/2015)... /CNW/ - Canada,s Research-Based Pharmaceutical Companies ... released report on Cost Drivers of Public Drug Plans in ... the report, the rates of change in drug costs have ... -0.8 percent in 2012/13 for a number of select public ... the costs of medicines without considering their overall impact on ...
(Date:4/1/2015)... CA (PRWEB) April 01, 2015 Holomic ... that can read both chromatographic and fluorescent rapid tests ... supplier of high performance, quantitative readers and is already ... The HRDR-400 is a first of its kind offering ... one instrument. , Dr. Neven Karlovac, CEO of ...
Breaking Biology Technology:Emerson Ecologics Announces First Annual Conference for Integrative Healthcare Practitioners 2Emerson Ecologics Announces First Annual Conference for Integrative Healthcare Practitioners 3Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3Rx&D responds to PMPRB report: overall impact of medicines must always be considered 2Holomic to Introduce the First Dual, Chromatographic and Fluorescent Rapid Test Reader, the HRDR-400 2
Cached News: